EN 
KR Result of clinical phase 2b of PHP-201, new drug candidate for glaucoma treatment, announced in 2019 APAO in Bangkok(For more information, please refer to the link below)http://www.biospectator.com/view/news_view.php?varAtcId=7329
pH Pharma “Plan to finalize licensing-out of glaucoma treatment…Initiate to go IPO”
“We are fast bio ventures with Development and Research model” Jaesik Kim, CEO, says(For more information, please refer to the link below)http://www.thebell.co.kr/free/content/ArticleView.asp?key=201903040100002050000125&lcode=00&page=1&svccode=00
Jae-sik Kim, CEO of PH Pharma “Targeting the global market with glaucoma drugs”
Specializes in glaucoma, which is common in AsiansDevelops treatment for non-alcoholic steatohepatitis Secured multiple chemical anticancer toxin molecules(For more information, please refer to the link below)http://news.hankyung.com/article/read/201811224326f
‘pH Pharma’s Global Strategy’. The reason why licensing-in of German and Belgian new drug candidates
Hoyoung Huh, CEO, who has experience in IPO, M&A in global biotech, founded pH Pharma in 2015..licensing-in of new drug candidates from around the world, development within short-term and technology transfer strategy..phase 2b for glaucoma treatment completed and phase 1b for Non-alcoholic steatohepatitis treatment progressed(For more information, please refer to...